Priorities for tuberculosis research - gov.uk 2016-08-02¢  Priorities for tuberculosis...

download Priorities for tuberculosis research - gov.uk 2016-08-02¢  Priorities for tuberculosis research: A report

of 96

  • date post

    04-Apr-2020
  • Category

    Documents

  • view

    1
  • download

    0

Embed Size (px)

Transcript of Priorities for tuberculosis research - gov.uk 2016-08-02¢  Priorities for tuberculosis...

  • For research on diseases of poverty UNICEF • UNDP • World Bank • WHO

    Priorities for tuberculosis research A report of the Disease reference group on TB, leprosy and Buruli ulcer

  • For research on diseases of poverty UNICEF • UNDP • World Bank • WHO

    Priorities for tuberculosis research A report of the Disease reference group on TB, leprosy and Buruli ulcer

  • Cover picture: WHO/Stop TB

    Design and layout: Lisa Schwarb, Lausanne

    WHO Library Cataloguing-in-Publication Data:

    Priorities for tuberculosis research: A report of the Disease

    reference group report on TB, leprosy and Buruli ulcer.

    1.Tuberculosis - prevention and control. 2.Tuberculosis - therapy.

    3.Tuberculosis, Pulmonary - prevention and control. 4.Operations

    research. I.Special Programme for Research and Training in

    Tropical Diseases. II.World Health Organization.

    ISBN 978 92 4 150597 0 (NLM classification: WF 300)

    Copyright © World Health Organization on behalf of the Special

    Programme for Research and Training in Tropical Diseases 2013

    All rights reserved.

    The use of content from this health information product for all

    non-commercial education, training and information purposes is

    encouraged, including translation, quotation and reproduction,

    in any medium, but the content must not be changed and full

    acknowledgement of the source must be clearly stated. A copy

    of any resulting product with such content should be sent to

    TDR, World Health Organization, Avenue Appia, 1211 Geneva 27,

    Switzerland. TDR is a World Health Organization (WHO) executed

    UNICEF/UNDP/World Bank/World Health Organization Special

    Programme for Research and Training in Tropical Diseases.

    This information product is not for sale. The use of any informa-

    tion or content whatsoever from it for publicity or advertising,

    or for any commercial or income-generating purpose, is strictly

    prohibited. No elements of this information product, in part or in

    whole, may be used to promote any specific individual, entity or

    product, in any manner whatsoever.

    The designations employed and the presentation of material

    in this health information product, including maps and other

    illustrative materials, do not imply the expression of any opinion

    whatsoever on the part of WHO, including TDR, the authors or

    any parties cooperating in the production, concerning the legal

    status of any country, territory, city or area, or of its authorities,

    or concerning the delineation of frontiers and borders.

    Mention or depiction of any specific product or commercial

    enterprise does not imply endorsement or recommendation by

    WHO, including TDR, the authors or any parties cooperating in

    the production, in preference to others of a similar nature not

    mentioned or depicted.

    The views expressed in this health information product are those

    of the authors and do not necessarily reflect those of WHO, in-

    cluding TDR. WHO, including TDR, and the authors of this health

    information product make no warranties or representations re-

    garding the content, presentation, appearance, completeness or

    accuracy in any medium and shall not be held liable for any dam-

    ages whatsoever as a result of its use or application. WHO, includ-

    ing TDR, reserves the right to make updates and changes without

    notice and accepts no liability for any errors or omissions in this

    regard. Any alteration to the original content brought about by

    display or access through different media is not the responsibil-

    ity of WHO, including TDR, or the authors. WHO, including TDR,

    and the authors accept no responsibility whatsoever for any inac-

    curate advice or information that is provided by sources reached

    via linkages or references to this health information product.

  • 3PRIORITIES FOR TUBERCULOSIS RESEARCH

    Members of the WHO TDR DRG for TB, leprosy and Buruli ulcer ......................................................................... 6

    Career Development Fellow ........................................................................................................................................................................ 7

    Abbreviations and acronyms ..................................................................................................................................................................... 8

    Executive summary............................................................................................................................................................................................ 10

    1 Introduction ................................................................................................................................................................................................. 11

    2 Methodology................................................................................................................................................................................................ 12

    2.1 Disease reference group ................................................................................................................................................................. 12 2.2 Identifying research priorities .................................................................................................................................................... 12 2.3 Review ........................................................................................................................................................................................................ 13 2.3 Structure of the report ..................................................................................................................................................................... 13

    3 Epidemiology ............................................................................................................................................................................................... 14

    3.1 Burden of disease ................................................................................................................................................................................ 14 3.2 Latent tuberculosis infection ...................................................................................................................................................... 15 3.3 Multi-drug resistant TB .................................................................................................................................................................... 15 3.4 HIV-associated TB ................................................................................................................................................................................ 15 3.5 TB in children ......................................................................................................................................................................................... 16

    4 TB vaccines ..................................................................................................................................................................................................... 19

    4.1 New vaccines ......................................................................................................................................................................................... 19 4.1.1 Overvie w of future TB vaccination strategies ............................................................................................... 19 4.1.2 Efficacy of BCG ................................................................................................................................................................ 19 4.1.3 Safety of BCG ................................................................................................................................................................... 20 4.2 New vaccines against TB ................................................................................................................................................................. 20 4.2.1 Antigen discovery .......................................................................................................................................................... 20 4.2.2 Vaccine design ................................................................................................................................................................ 21 4.2.3 Preclinical studies ......................................................................................................................................................... 21 4.2.4 Assessment of safety and reactogenicity in humans................................................................................. 22 4.2.5 Assessing immunogenicity in human trials .................................................................................................... 22 4.2.6 Biomarkers of protection .......................................................................................................................................... 23 4.2.7 Assessment of efficacy in humans ....................................................................................................................... 23 4.3 TB immunotherapy.....................